scispace - formally typeset
J

Justin Stebbing

Researcher at Imperial College London

Publications -  660
Citations -  22342

Justin Stebbing is an academic researcher from Imperial College London. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 68, co-authored 633 publications receiving 18697 citations. Previous affiliations of Justin Stebbing include Imperial College Healthcare & Royal Surrey County Hospital.

Papers
More filters
Journal ArticleDOI

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.

TL;DR: It is suggested that baricitinib could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and the inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.
Journal ArticleDOI

COVID-19: combining antiviral and anti-inflammatory treatments

TL;DR: Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, and convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.
Journal ArticleDOI

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

TL;DR: These data confirm the independent prognostic effect of CTC count on progression-free survival and overall survival and also improves the prognostication of metastatic breast cancer when added to full clinicopathological predictive models, whereas serum tumour markers do not.
Journal ArticleDOI

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martin, +622 more
- 01 Dec 2017 - 
TL;DR: 1 year of extended adjuvant therapy with neratinib, administered after chemotherapy and trastuzumab, significantly reduced the proportion of clinically relevant breast cancer relapses-ie, those that might lead to death, such as distant and locoregional relapses outside the preserved breast-without increasing the risk of long-term toxicity.
Journal ArticleDOI

Highly Active Antiretroviral Therapy and the Incidence of Non–AIDS-Defining Cancers in People With HIV Infection

TL;DR: Since the introduction of HAART, there has been a significantly increased risk of NADCs, which has now stabilized, and a number of factors are associated with this increased risk, including HAART use.